If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVenture Life Regulatory News (VLG)

Share Price Information for Venture Life (VLG)

Share Price is delayed by 15 minutes
Get Live Data
66.50    -0.50 (-0.75%)
Bid:
66.00
Ask:
67.00
Spread: 1.00 (1.515%)
Market Cap: £80.07m
VLG Live PriceLast checked at - London Stock Exchange

Intraday Venture Life Share Chart

UltraDEX update

30 Apr 2018 07:00

RNS Number : 4552M
Venture Life Group PLC
30 April 2018
 

Venture Life Group plc

("Venture Life" or "the Company")

 

UltraDEX update

 

Venture Life (AIM: VLG), the international consumer self-care group focused on developing, manufacturing and commercialising products for the self-care market announces an update on the UltraDEX brand. The Company has extended its agreement with key French distributor La Brosse et Dupont SAS ("La Brosse") to include the UltraDEX Sensitive toothpaste. The launch will take place in H2 2018 and follows the successful launch of the original UltraDEX range in Q1 2018 in France.

 

Founded in 1932, La Brosse is a former subsidiary of LVMH Moet Hennessy Louis Vuitton S.E. It serves customers through large and medium commercial outlets throughout France, including Leclerc and Carrefour, and has market leading products within the oral healthcare space. Le Brosse launched the original UltraDEX range into the French market during March 2018 and is building up a presence in the grocery multiples.

 

UltraDEX was also partnered in Italy and the Nordics in 2017, and after delivery of product in Q4 2017, these partners have also launched UltraDEX into their respective markets during H1 2018. Both partners are building a presence for the mouthwash, toothpaste and spray products in pharmacies and dentists, and early indications are positive for the sell through.

 

Separately, the Company announces the launch of the new UltraDEX 'One GoÔ' range in all 797 of the Superdrug stores in the UK from June 2018. UltraDEX 'One Go' is another new innovative line extension from the Company, providing single use sachets of the UltraDEX mouthwash.

 

Jerry Randall, CEO of Venture Life commented: "The extension of this agreement with La Brosse is a real testament to the continued international success of UltraDEX, particularly at such an early stage in their launch of the UltraDEX range in France. I am delighted with the continued commercial development of the UltraDEX brand both in the UK and internationally, and we look forward updating the market further throughout the rest of the year.

 

"It's also great news that our new product, UltraDEX 'One Go', has been so quickly adopted by one of the leading pharmacy chains, Superdrug, demonstrating our ability to rapidly develop and launch innovative new products into the consumer self-care channel, and we are hopeful to extend its presence further. Innovation is key to the growth of consumer brands, and Venture Life has the experience and capabilities to develop and commercialise such new products."

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR).

 

 

 

Enquiries

 

Venture Life Group PLC

+44 (0) 1344 578 004

Jerry Randall, Chief Executive Officer

Adrian Crockett, Chief Financial Officer

 

Northland Capital Partners Limited (Nominated Adviser and Joint Broker)

+44 (0) 20 3861 6625

Matthew Johnson/Edward Hutton (Corporate Finance)

Bob Pountney (Corporate Broking)

Turner Pope Investments (TPI) Ltd (Joint Broker)

+44 (0) 20 3621 4120

Andy Thacker

Walbrook PR

venturelife@walbrookpr.com or +44 (0) 20 7933 8780

Anna Dunphy/Paul McManus

+44 (0) 7876 741 001 / +44 (0) 7980 541 893

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
UPDLLFLESDIDFIT
Date   Source Headline
8th May 20182:54 pmRNSHolding(s) in Company
30th Apr 20187:00 amRNSUltraDEX update
17th Apr 20187:00 amRNSDirector/PDMR Shareholding
5th Apr 20187:00 amRNSDirector/PDMR Shareholding
27th Mar 20187:00 amRNSDirector/PDMR Shareholding
26th Mar 20187:00 amRNS2018 LTIP and Grant of Options to PDMRs
22nd Mar 20187:00 amRNSFinal Results
5th Mar 20187:00 amRNSNotice of analyst & investor results briefings
16th Feb 20187:00 amRNSInvestor presentation
13th Feb 20187:00 amRNSCommerical update
31st Jan 20187:00 amRNSTrading update
8th Jan 20187:00 amRNSEuropean Business Awards 'Ones to Watch List'
24th Nov 20177:00 amRNSNew exclusive partner secured in Austrian market
23rd Nov 201711:14 amRNSUK Bond Network presentation
14th Nov 20177:00 amRNSVox Markets
30th Oct 20177:00 amRNSUltraDEX update
10th Oct 20177:00 amRNSHolding(s) in Company
2nd Oct 20177:00 amRNSFDA approval for the US market
21st Sep 20177:00 amRNSHalf-year Report
7th Sep 20177:00 amRNSDistribution partners and Lubatti China update
4th Sep 20177:00 amRNSNotice of Results
7th Aug 20174:24 pmRNSDirector/PDMR Shareholding
19th Jul 20177:00 amRNSDistribution partner for UltraDEX & patent update
12th Jul 20177:00 amRNSTrading update
23rd May 201710:59 amRNSResult of AGM
23rd May 20177:00 amRNSUltraDEX Patent Grants and Distribution Update
18th May 20177:00 amRNSTwo new CE Mark approvals
10th May 20179:00 amRNS'1000 Companies to Inspire Britain' 2017 report
4th May 20177:00 amRNSChange of Adviser
4th May 20177:00 amRNSGrant of Options
25th Apr 20177:00 amRNS2017 Long Term Incentive Plan and Grant of Options
29th Mar 20173:36 pmRNSUK Investor Show attendance
23rd Mar 20177:00 amRNSFinal Results
1st Mar 20177:00 amRNSDirectorate Change
1st Feb 20171:08 pmRNSHolding(s) in Company
31st Jan 20174:39 pmRNSInvestor Day presentation now available
26th Jan 20177:00 amRNSTrading update
20th Dec 20167:00 amRNSInvestor evening
29th Nov 20166:06 pmRNSHolding(s) in Company
28th Nov 20167:00 amRNSAppointment of Vox Markets
17th Nov 20167:00 amRNSInvestor evening
14th Nov 20167:00 amRNSTrading update
10th Nov 20167:00 amRNSDirectorate Change
10th Oct 20167:00 amRNSUltraDEX advertising launch
7th Oct 201612:10 pmRNSIssue of Equity
29th Sep 20167:00 amRNS2016 LTIP adopted & Grant of Options
21st Sep 20167:00 amRNSHalf-year Report
21st Sep 20167:00 amRNSAppointment of joint broker
7th Sep 20167:00 amRNSNotice of Results
29th Jul 20167:00 amRNSPre-close trading statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.